glp-1
16 stories tagged "glp-1"
A Daily Scoop of Chicory Fiber Eased Knee Arthritis, and It Moved the Same Gut Hormone as Ozempic
Twenty grams of chicory fiber a day matched a physiotherapy app for knee arthritis pain, and only one person in the fiber group quit. The hormone it nudged is the one Ozempic is built to imitate.
Metabolic & WeightOrforglipron Reaches Deep Into the Brain's Reward Circuit and Turns the Dopamine Down
In mice engineered with human GLP-1 receptors, the new oral pills reached the central amygdala, a deep reward hub, and thinned the dopamine payoff of eating for pleasure. The government's addiction institute is already watching.
Metabolic & WeightThe GLP-1s That Barely Move the Scale Don't Cause Hair Loss, and That's the Clue Everyone Missed
Women on semaglutide shed hair at about twice the rate of men, and the weakest GLP-1s show almost no signal, which points the cause away from the follicle and straight at how fast the weight comes off.
Metabolic & WeightThe Mice Ate More and Got Leaner. The Switch Was One Amino Acid, Turned Down.
USC mice on a low-protein, methionine-tuned diet ate as many calories as the junk-food group and still lost fat, while their own bodies pumped out more GLP-1. The scientist behind it also owns the company selling longevity diets.
Metabolic & WeightBoth Groups Lost the Same Seven Kilos. Only the Calorie Counters Had to White-Knuckle It.
In an 18-month Adelaide trial, fasting and daily calorie-cutting stripped off the same seven kilos, but for the counters part of that loss ran on constant conscious restraint the fasters' scores never showed.
Metabolic & WeightSwitch Off One Protein Called Mitch, and Cells Start Eating Their Own Fat
Women with obesity carry more of it. Disable it in mice and they turn lean and muscular at once, the opposite of what the injectable weight-loss drugs do to your body.
Metabolic & WeightObesity Stopped Denting Older Adults' Metabolic Numbers: In the Young It's Biting Harder Than Ever
For middle-aged and older adults, extra weight no longer tracks with the cardiovascular damage it once did. For the young, the same fat is biting harder and earlier. The lab panels converged; the fat didn't.
Metabolic & WeightThe Obesity 'Revolution' Everyone's Promising Comes From People Who'd Cash In On It
A new commentary says the GLP-1 era is just the prelude to a bigger obesity "revolution." The authors have direct financial stakes in what comes next, and the celebrated new pill loses less weight than the shot.
Brain & AgingA viral diabetes-and-dementia explainer left out the trial that just killed its big drug story
A widely shared "ten ways diabetes and dementia are linked" explainer is going around this week, and it skips the Phase 3 trial that, weeks earlier, demolished its brain-protection story for semaglutide.
Drugs & FDAMedicare's Product-Hopping Loophole Is Back On The Chopping Block. The Bigger Pharma Giveaway Isn't.
The Trump administration on Thursday proposed closing the product-hopping loophole that lets drugmakers reset Medicare's negotiation clock by tweaking inactive ingredients. It is the same fix the same administration quietly tabled in October.
Metabolic & WeightLilly's triple agonist hit 30% weight loss. The glucagon bet is why.
Lilly's triple agonist hit nearly 30% weight loss at 104 weeks at ADA 2026. The glucagon bet is what makes retatrutide different from semaglutide and Mounjaro, and it's what makes the open safety signals different too.
CancerOzempic's 30 Percent Breast-Cancer Headline, and the Trial Evidence It Walked Past
A single-system observational study at ASCO 2026 attached a roughly 30% lower breast-cancer rate to GLP-1 use. The randomized record already on the table is quieter.
Metabolic & WeightRetatrutide's Triple-Receptor Triumph Came With a One-in-Five Skin-Sensation Signal Nobody Wanted to Linger On
Eli Lilly's investigational retatrutide hit bariatric-surgery-level weight loss at ADA 2026. The highest-dose arm of TRIUMPH-4 also saw 20.9% of patients report abnormal skin sensations, and a small cardiac imbalance turned up in the type-2 trial. Both got far less stage time than the headline numbe
Metabolic & WeightThe Oral GLP-1 Race Just Got a Third Serious Contender, and Its Curve Was Still Climbing
Structure Therapeutics' once-daily oral GLP-1 aleniglipron hit 11.3 percent placebo-adjusted weight loss at 36 weeks and kept climbing in the open label. The catch: oral semaglutide and orforglipron already cleared the FDA.
Metabolic & WeightThe Ozempic 'Resistance' Headline the Data Didn't Quite Earn
A new study identifies PAM-gene variants tied to weaker six-month HbA1c response to GLP-1 diabetes drugs, but the 'why Ozempic may not work' framing imports a weight-loss conclusion the paper doesn't reach, and the buried trials that used longer-acting GLP-1 drugs showed no carrier effect at all.
Metabolic & WeightA gut hormone keeps showing up in the brain's reward circuit, and 600,000 veterans just gave us the biggest hint yet that it matters
A VA cohort of 606,000 diabetic veterans on GLP-1 drugs showed lower risks of new substance use disorders and large drops in overdose and drug-related death versus a peer diabetes drug. The mechanism story is where it gets interesting.